COMP <GO>
SKYE vs ACXP // GROSS PROFIT MARGIN
Skye Bioscience Inc. (NASDAQ) VS. Acurx Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SKYE 1
— ACXP 1
■ METRIC PARITY
LAST: $1.31 (-13.82%) • MKT CAP: $5.8M
gross-margins
—
LAST: $1.07 (0.00%) • MKT CAP: $5.9M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SKYE VS. ACXP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SKYE | ACXP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.0 | 26.6 | +4.35 | SKYE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.8M | $5.9M | -$148.3K | ACXP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SKYE REV | ACXP REV | SKYE GROSS % | ACXP GROSS % | SKYE FCF | ACXP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$43.1M | -$6.8M |
| FY 2024 | $0 | $0 | — | — | -$26.8M | -$10.4M |
| FY 2023 | $0 | $0 | — | — | -$14.0M | -$9.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SKYE // BETA —
ACXP // BETA —